Zydus gets COFEPRIS nod to market Bhava to treat various cancers EP News Bureau Jul 22, 2024 Bhava, a Bevacizumab biosimilar and will be marketed in different strengths of 100 mg/4 ml and 400 mg/16 ml
NATCO announces ANDA filing for generic olaparib tablets in US EP News Bureau Feb 13, 2023 Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer
BDR Pharma launches generic Rucaparib to treat advanced ovarian and prostate cancers EP News Bureau May 27, 2021 Rucaparib is launched under the brand name BDPARIB in two strengths of 200 mg and 300 mg
LYNPARZA (olaparib) get three new approvals in Japan EP News Bureau Dec 29, 2020 Approvals in three types of cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials
Zydus Cadila gets US FDA approval for Doxorubicin Hydrochloride Liposome Injection EP News Bureau Sep 11, 2020 Liposomal doxorubicin is a chemotherapeutic agent that is used alone or with other treatments/medications to treat certain types…
AstraZeneca-Merck’s Lynparza wins approval in China for ovarian cancer treatment, Reuters Dec 5, 2019 The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or…